Wang BY, et al. - In order to assess if survival is better after neoadjuvant chemoradiotherapy plus surgery (CRT-S) vs definitive chemoradiotherapy (dCRT) in patients with locally advanced esophageal squamous cell carcinoma (SCC), researchers analyzed 5,832 patients with clinical stage II and III esophageal SCC who underwent curative treatment from 2008 to 2014 from the Taiwan Cancer Registry. Outcomes revealed better overall survival in correlation with neoadjuvant chemoradiotherapy and esophagectomy vs dCRT in these patients. The 3-year overall survival rate for patients treated with CRT-S was 41.1% vs 17.9% for those who had dCRT.